Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than 10 million people ...

New research presented today (Wednesday) at the Federation of European Neuroscience Societies (FENS) Forum 2026 has ...

Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the completion of enrollment for the REPLACE™ Phase 1b ...

A drug that showed promise in treating a sleep disorder could potentially help slow symptoms, experts say.